Notre Dame Journal of Law, Ethics & Public Policy Volume 25 Issue 2 Symposium On Health Care: Health, Ethics, & Article 19 the Law January 2014 The Other War on Drugs: Federal Preemption, the FDA, and Prescription Drugs after Wyeth v. Levine Joseph F. Petros III Follow this and additional works at: http://scholarship.law.nd.edu/ndjlepp Recommended Citation Joseph F. Petros III, The Other War on Drugs: Federal Preemption, the FDA, and Prescription Drugs after Wyeth v. Levine, 25 Notre Dame J.L. Ethics & Pub. Pol'y 637 (2012). Available at: http://scholarship.law.nd.edu/ndjlepp/vol25/iss2/19 This Note is brought to you for free and open access by the Notre Dame Journal of Law, Ethics & Public Policy at NDLScholarship. It has been accepted for inclusion in Notre Dame Journal of Law, Ethics & Public Policy by an authorized administrator of NDLScholarship. For more information, please contact
[email protected]. NOTES THE OTHER WAR ON DRUGS: FEDERAL PREEMPTION, THE FDA, AND PRESCRIPTION DRUGS AFTER WYETH V. LEVINE JOSEPH F. PETROS 111* INTRODUCTION Amidst the debates over health care reform in the United States, there are several common desires that most Americans share: lower costs, greater availability, and continued innovation. Yet as Americans have fixed their attentions on reform legisla- tion, few outside academia have noticed a recent and potent blow to these desires in one of the major sectors of the health care industry. This is, perhaps, because the blow came from the "least dangerous"' branch of the federal government. The case was Wyeth v. Levine,2 and the issue was the doctrine of federal preemption as it applies to the regulation of prescription drug warning labels by the Food and Drug Administration (FDA).